Investigational drug · Phase 3
Prasinezumab
Also called: RO7046015, PRX002
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Parkinson's Disease, Parkinsons Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "Prasinezumab"
First trial start
2017
Jun 27, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Prasinezumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease
- Parkinsons Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Prasinezumab" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07174310 · 900 participants (planned) · Start Nov 24, 2025 · Primary completion Jun 30, 2029
Drug: Prasinezumab; Placebo · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fullerton, California · 192 sites in all
- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04777331 · 586 participants · Start May 5, 2021 · Primary completion Sep 11, 2024
Drug: Prasinezumab; Placebo · For: Parkinsons Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fullerton, California · 110 sites in all
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03100149 · 316 participants · Start Jun 27, 2017 · Primary completion Nov 27, 2019
Drug: RO7046015; RO7046015 and 1 more · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fullerton, California · 55 sites in all
- Prevent Cognitive Decline in GBA-associated Parkinson's DiseasePivotal-lookingRecruiting
University Hospital TuebingenAcademic, hospital or other
NCT07055087 · 120 participants (planned) · Start Oct 2026 · Primary completion Dec 2030
Drug: Prasinezumab; Sodium Chloride · For: Parkinson's Disease
Sites: Paris, France; Dresden, Germany; Tübingen, Germany · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Target engagement without clinical benefit: a systematic review, mechanism-concordant meta-analysis, and research agenda for Parkinson's disease immunotherapy.
Zhou X, Richard SA, Lan Z, et al. · Immunotherapy 2026
- Multitargeted drug strategies for Alzheimer's and Parkinson's diseases.
Khan AU, Abdullah A, Naqvi SF, et al. · Z Naturforsch C J Biosci 2026
- The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review.
Coles D, Kalyana A, Khalil S, et al. · Parkinsons Dis 2026
- The conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheses.
Bougea A · Ther Adv Neurol Disord 2026
- Progress of Immunotherapies in Parkinson's Disease.
Peng Y, Kang XH, Yao SY, et al. · CNS Neurosci Ther 2026
- Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Nikolcheva T, Pagano G, Anzures-Cabrera J, et al. · Lancet 2026
Also in development for Parkinson's Disease
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- GM1Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- BIA 28-6156Phase 21 trial
Bial R&D Investments, S.A. · Parkinson's Disease
- MT101-5Phase 21 trial
Mthera Pharma Co., Ltd. · Parkinson's Disease
- ND0612ND0612HPhase 21 trial
NeuroDerm Ltd. · Parkinson's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.